| 1. |
- Ludvigsson, Johnny, et al.
(författare)
-
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
- 2012
-
Ingår i: New England Journal of Medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 366:5, s. 433-442
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes.METHODS: We studied 334 patients, 10 to 20 years of age, with type 1 diabetes, fasting C-peptide levels of more than 0.3 ng per milliliter (0.1 nmol per liter), and detectable serum GAD65 autoantibodies. Within 3 months after diagnosis, patients were randomly assigned to receive one of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of placebo. The primary outcome was the change in the stimulated serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-month visit. Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate of hypoglycemia, and fasting and maximum stimulated C-peptide levels.RESULTS: The stimulated C-peptide level declined to a similar degree in all study groups, and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group (P=0.10). The use of GAD-alum as compared with placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate. Adverse events were infrequent and mild in the three groups, with no significant differences.CONCLUSIONS: Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Peters, Gregory, 1970, et al.
(författare)
-
A Swedish comment on ‘review: the availability of life-cycle studies in Sweden’
- 2019
-
Ingår i: International Journal of Life Cycle Assessment. - : Springer Science and Business Media LLC. - 1614-7502 .- 0948-3349. ; 24:10, s. 1758-1759
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The article entitled ‘Review: the availability of life-cycle studies in Sweden’ by Croft and colleagues (January 2019, volume 24, issue 1, pages 6–11) has puzzled many researchers in Sweden. The stated purpose of the article is to review the availability of water and carbon footprinting studies and life-cycle assessment (LCA) studies in Sweden. Despite its title and purpose suggesting otherwise, the article appears to be about the accessibility of life-cycle case studies from Sweden in South Africa. It is problematic that the article claims to be a review in the title and text, but is presented by the journal as a commentary. We believe that the article’s method is unclear and that its title and results are misleading. The authors of the article found only 12 academic papers, 10 academic theses, 8 company reports, and 1 presentation. This result significantly underestimates the actual production and availability of Swedish LCA case studies.
|
|
| 5. |
- Rodanaki, Maria, 1987-, et al.
(författare)
-
The Incidence of Childhood Thyrotoxicosis Is Increasing in Both Girls and Boys in Sweden
- 2019
-
Ingår i: Hormone Research in Paediatrics. - : S. Karger. - 1663-2818 .- 1663-2826. ; 91:3, s. 195-202
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: We found an increase in the incidence rate (IR) of childhood thyrotoxicosis (CT) during the 1990s in central Sweden. The optimal treatment method for CT is a subject that is still debated upon.OBJECTIVES: To investigate whether the increase in IR of CT in Sweden persists and to study the treatment outcome.METHOD: Children <16 years of age diagnosed with CT during 2000-2009 and living in 1 of 5 counties in central Sweden were identified retrospectively using hospital registers. Data on clinical and biochemical characteristics and outcomes of treatment were collected from medical records. The corresponding data from 1990 to 1999 were pooled with the new data.RESULTS: In total, 113 children were diagnosed with CT during 1990-2009 in the study area. The overall IR was 2.2/100,000 person-years (95% CI 1.2-2.5/100,000 person-years). The IR was significantly higher during 2000-2009 than during 1990-1999 (2.8/100,000 [2.2-3.6] vs. 1.6/100,000 person-years [1.2-2.2], p = 0.006). The increase was significant for both sexes. Seventy percent of the patients who completed the planned initial treatment with antithyroid drugs (ATDs) and were not lost to follow-up relapsed within 3 years. Boys tended to relapse earlier than girls (6.0 months after drug withdrawal [95% CI 1.9-10.0] vs. 12.0 months [95% CI 6.8-17.3], p = 0.074).CONCLUSIONS: The IR of CT is increasing in both girls and boys. Relapse rate after withdrawal of ATD treatment is 70%. Boys tend to relapse earlier than girls, and this needs to be further investigated.
|
|
| 6. |
- Thuresson, Ann-Charlotte, et al.
(författare)
-
A novel heterozygous variant in FGF9 associated with previously unreported features of multiple synostosis syndrome 3
- 2021
-
Ingår i: Clinical Genetics. - : John Wiley & Sons. - 0009-9163 .- 1399-0004. ; 99:2, s. 325-329
-
Tidskriftsartikel (refereegranskat)abstract
- Human multiple synostoses syndrome 3 is an autosomal dominant disorder caused by pathogenic variants in FGF9. Only two variants have been described in FGF9 in humans so far, and one in mice. Here we report a novel missense variant c.566C>G, p.(Pro189Arg) in FGF9. Functional studies showed this variant impairs FGF9 homodimerization, but not FGFR3c binding. We also review the findings of cases reported previously and report on additional features not described previously.
|
|
